Literature DB >> 25176450

MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer.

Wei Wang1, Fang Ren1, Qinghua Wu1, Dazhi Jiang2, Hongjun Li2, Huirong Shi1.   

Abstract

MicroRNAs (miRNAs) have been shown to play an important role in diverse biological processes and cancer progression. The objective of the present study was to investigate the role of miR-497 in ovarian cancer angiogenesis. We found that miR-497 expression was downregulated in human ovarian cancer tissues, and the low miR-497 expression was significantly associated with increased angiogenesis. Functionally, exogenous expression of miR-497 suppressed the ability of ovarian cancer cells to promote capillary tube formation of endothelial cells. We further disclosed that miR-497 exerted its function of anti-angiogenesis by suppressing VEGFA expression in ovarian cancer cells and, in turn, impairing the VEGFR2-mediated PI3K/AKT and MAPK/ERK pathways. Our findings suggest that downregulation of miR-497 may contribute to angiogenesis in ovarian cancer. miR-497 may be a promising candidate target for prevention and treatment of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25176450     DOI: 10.3892/or.2014.3439

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  46 in total

1.  MicroRNA-497 suppresses cell proliferation and induces apoptosis through targeting PBX3 in human multiple myeloma.

Authors:  Tianhua Yu; Xuanhe Zhang; Lirong Zhang; Yali Wang; Hongjuan Pan; Zhihua Xu; Xiaochuan Pang
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

2.  SPARCL1 suppresses the proliferation and migration of human ovarian cancer cells via the MEK/ERK signaling.

Authors:  Yan Ma; Yuan Xu; Li Li
Journal:  Exp Ther Med       Date:  2018-08-07       Impact factor: 2.447

3.  Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.

Authors:  Xiuhui Chen; Lingegowda S Mangala; Linda Mooberry; Emine Bayraktar; Santosh K Dasari; Shaolin Ma; Cristina Ivan; Karem A Court; Cristian Rodriguez-Aguayo; Recep Bayraktar; Sangram Raut; Nirupama Sabnis; Xianchao Kong; Xianbin Yang; Gabriel Lopez-Berestein; Andras G Lacko; Anil K Sood
Journal:  Oncogene       Date:  2019-07-09       Impact factor: 9.867

4.  Downregulation of microRNA-497 is associated with upregulation of synuclein γ in patients with osteosarcoma.

Authors:  Liang Wang; Hongwei Gao; Ningji Gong; Mingzhi Gong
Journal:  Exp Ther Med       Date:  2016-10-26       Impact factor: 2.447

5.  microRNA-497 overexpression decreases proliferation, migration and invasion of human retinoblastoma cells via targeting vascular endothelial growth factor A.

Authors:  Jianjun Li; Yinghui Zhang; Xiuchao Wang; Ruibo Zhao
Journal:  Oncol Lett       Date:  2017-04-24       Impact factor: 2.967

6.  MicroRNA-134 targets KRAS to suppress breast cancer cell proliferation, migration and invasion.

Authors:  Xiaomei Su; Ling Zhang; Hua Li; Peng Cheng; Yajie Zhu; Zhen Liu; Yu Zhao; Hongyu Xu; Dong Li; Hui Gao; Tao Zhang
Journal:  Oncol Lett       Date:  2017-01-25       Impact factor: 2.967

7.  MicroRNA-133b inhibits proliferation and invasion of ovarian cancer cells through Akt and Erk1/2 inactivation by targeting epidermal growth factor receptor.

Authors:  Xiaoqin Liu; Guohong Li
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  miRNA involvement in angiogenesis in age-related macular degeneration.

Authors:  Lei Wang; Amy Yi Wei Lee; Jonathan P Wigg; Hitesh Peshavariya; Ping Liu; Hong Zhang
Journal:  J Physiol Biochem       Date:  2016-06-27       Impact factor: 4.158

9.  MicroRNA-497 suppresses osteosarcoma tumor growth in vitro and in vivo.

Authors:  Liang Ge; Baisong Zheng; Minghe Li; Liang Niu; Zhihong Li
Journal:  Oncol Lett       Date:  2016-01-29       Impact factor: 2.967

Review 10.  Tumor Immune Microenvironment and Its Related miRNAs in Tumor Progression.

Authors:  Yingying Xing; Guojing Ruan; Haiwei Ni; Hai Qin; Simiao Chen; Xinyue Gu; Jiamin Shang; Yantong Zhou; Xi Tao; Lufeng Zheng
Journal:  Front Immunol       Date:  2021-05-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.